ESR1 and breast carcinoma: Preventative endocrine therapy with selective estrogen receptor modulators (SERMs) such as tamoxifen has delivered encouraging results in preventing breast cancer, but the utilization of tamoxifen for risk reduction has been limited, in part due to its side effects [7].